Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

Verfasser: Brunner, Andrew M.
Esteve, Jordi
Porkka, Kimmo
Knapper, Steve
Traer, Elie
Scholl, Sebastian
Garcia-Manero, Guillermo
Vey, Norbert
Wermke, Martin
Janssen, Jeroen J. W. M.
Narayan, Rupa
Fleming, Shaun
Loo, Sun
Tovar, Natalia
Kontro, Mika
Ottmann, Oliver G.
Naidu, Purushotham
Sun, Haiying
Han, May
White, Roisin
Zhang, Na
Mohammed, Anisa
Sabatos-Peyton, Catherine A.
Steensma, David P.
Rinne, Mikael L.
Borate, Uma M.
Wei, Andrew H.
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Brunner , A M , Esteve , J , Porkka , K , Knapper , S , Traer , E , Scholl , S , Garcia-Manero , G , Vey , N , Wermke , M , Janssen , J J W M , Narayan , R , Fleming , S , Loo , S , Tovar , N , Kontro , M , Ottmann , O G , Naidu , P , Sun , H , Han , M , White , R , Zhang , N , Mohammed , A , Sabatos-Peyton , C A , Steensma , D P , Rinne , M L , Borate , U M & Wei , A H 2023 , ' Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes ' , American Journal of Hematology . https://doi.org/10.1002/ajh.27161
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26885686
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://research.vumc.nl/en/publications/450a9239-0b36-4ede-a9bc-709d6d1560b7